Werewolf Therapeutics
Update in progressHOWL (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Werewolf Therapeutics, Inc. is a biopharmaceutical company developing immune-stimulating therapies for cancer and immune diseases. Using its PREDATOR platform, it creates conditionally activated INDs to improve safety and efficacy. Lead candidates include WTX-124 (IL-2 INDUKINE) and WTX-330 (IL-12 INDUKINE) for solid tumors. Additional programs target IFN-α, IL-10, IL-21, IL-18, STEAP1, and CDH6. Founded 2017, based in Watertown, MA.
Company score
- Sentiment
- -0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.06
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Daniel J. Hicklin Ph.D.
- Founded2017
- Employees39
- Websitewerewolftx.com
Identifiers
- ISINUS95075A1079
- FIGIBBG00QXQ9XK4
- CUSIP95075A107
- CIK0001785530